Taguchi, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 （Shiba-Kyoritsu）

Position

Associate Professor
Page Top ▲

Career 【 Display / hide 】

  • 2010.04
    -
    2011.03

    日本学術振興会特別研究員

  • 2011.04
    -
    2013.03

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013.04
    -
    2017.03

    崇城大学　, 薬学部, 助教

  • 2018.04
    -
    2021.03

    慶應義塾大学, 薬学部, 専任講師

  • 2021.04
    -
    Present

    慶應義塾大学, 薬学部, 准教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 2006.03

    Kumamoto University, 薬学部

    University, Graduated

  • 2008.03

    Kumamoto University

    Graduate School, Completed, Master's course

  • 2011.03

    Kumamoto University

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士 (薬学), 熊本大学, 2011.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師, 2006.04

Page Top ▲
 

Books 【 Display / hide 】

  • Carbon monoxide-bound Hemoglobin-Vesicles: Current facts and potential medical applications.

    Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M, World Scientific Publishing Co. Pte. Ltd., 2021.12

    Scope: Chapter 6.10.,  Contact page： 849-865

  • ＤＤＳ先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017

    Scope: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

    Scope: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013

    Scope: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

    Scope: Chapter 6, pp.139-62

Page Top ▲

Papers 【 Display / hide 】

  • Methemoglobin-albumin clusters for cyanide detoxification

    Suzuki Y., Taguchi K., Okamoto W., Enoki Y., Komatsu T., Matsumoto K.

    Toxicology and Applied Pharmacology （Toxicology and Applied Pharmacology)  466   116472 2023.05

    ISSN  0041008X

    　View Summary

    Sodium nitrite (NaNO2) is a universal antidote for patients with cyanide poisoning. However, its use has serious drawbacks in terms of efficacy and safety. Herein, we present a promising antidote: methemoglobin (metHb)-albumin clusters. The metHb-albumin cluster is made by a metHb core wrapped by covalently bound human serum albumin. Spectral analyses proved that the metHb-albumin clusters possessed cyanide-binding properties similar to those of naked metHb. In vitro cell experiments showed that metHb-albumin clusters prevented the cyanide-induced inhibition of cytochrome c oxidase activity, resulting in a strong cytoprotective effect. In mice subjected to cyanide poisoning, metHb-albumin clusters reduced mortality and alleviated metabolic acidosis, while maintaining the activity of cytochrome c oxidase in organs; their efficacy was better than that of NaNO2. Furthermore, the oxygen carrying capacity was maintained in poisoned mice treated with metHb-albumin clusters and was low in those treated with NaNO2. These results indicate that metHb-albumin clusters could be a more effective and safer antidote against cyanide poisoning than NaNO2.

  • Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae.

    Igarashi Y, Takemura W, Liu X, Kojima N, Morita T, Chuang VTG, Enoki Y, Taguchi K, Matsumoto K

    The Journal of antimicrobial chemotherapy 78 （ 4 ） 991 - 999 2023.04

    ISSN  0305-7453

  • Comparison of the efficacy and safety of standard- and high-dose daptomycin: A systematic review and meta-analysis.

    Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Uchida M, Inoue J, Tanikawa K, Enoki Y, Taguchi K, Matsumoto K, Ueda T, Fujimura S, Mikamo H, Takesue Y, Mitsutake K

    British journal of clinical pharmacology 89 （ 4 ） 1291 - 1303 2023.04

    ISSN  0306-5251

  • The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease.

    Enoki Y, Nagai T, Hamamura Y, Osa S, Nakamura H, Taguchi K, Watanabe H, Maruyama T, Matsumoto K

    Journal of cachexia, sarcopenia and muscle 14 （ 1 ） 553 - 564 2023.02

    ISSN  2190-5991

  • Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis

    Tashiro S., Mihara T., Okawa R., Tanaka Y., Samura M., Enoki Y., Taguchi K., Matsumoto K., Yamagishi Y.

    European Journal of Pediatrics （European Journal of Pediatrics)   2023

    ISSN  03406199

    　View Summary

    We conducted a systematic review and meta-analysis to examine the efficacy profiles of metronidazole (MNZ) and vancomycin (VCM) in pediatric and adolescent patients with Clostridioides difficile infection (CDI). A systematic review and meta-analysis was conducted using four electronic databases (PubMed, Cochrane Library, Web of Science, and Clinicaltrials.gov) through July 6, 2022. We analyzed the clinical cure and recurrence rates to determine the efficacy of MNZ and VCM. The clinical cure rates in all included studies were not significantly different between MNZ and VCM (OR = 0.63; 95% CI = 0.36–1.10; I2 = 0%; P = 0.10). Subgroup analyses were performed separately for each region to account for regional differences in the CDI. MNZ treatment achieved significantly lower clinical cure rates than did VCM in the United States of America (USA) and Europe (OR = 0.42, 95% CI = 0.19–0.93, I2 = 0%, P = 0.03). Recurrence rates were not significantly different between MNZ and VCM (OR = 1.48, 95% CI = 0.62–3.53, I2 = 28%, P = 0.38). Conclusion: MNZ exhibited significantly lower clinical cure rates than did VCM in the US and Europe; therefore, it is not recommended for the management of CDI in pediatric and adolescent populations.What is Known:• The unavailability of robust data on recommendations of therapeutic agents for the management of Clostridioides difficile infections in children precludes effective antibiotic choice.What is New:• Metronidazole exhibited significantly lower clinical cure rates than did vancomycin in the United States of America and Europe and recurrence rate was not significantly different between metronidazole and vancomycin; therefore, it is not recommended for the management of Clostridioides difficile infection in children.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    YAKUGAKU ZASSHI 138   1381 - 1389 2018

    Article, review, commentary, editorial, etc. (scientific journal), Single Work

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Research on pharmacokinetic analysis and safety evaluation for clinical development of artificial blood.

    Kazuaki Taguchi

    日本薬物動態学会第36年会, 

    2021.11
    , 

    Oral presentation (invited, special)

  • ヘモグロビンを用いた一酸化炭素製剤の開発

    田口和明，小田切優樹，松元一明

    第28回日本血液代替物学会年次大会, 

    2021.10
    , 

    Symposium, workshop panel (nominated)

  • 健康セミナー参加者を対象としたセルフメディケーション税制に関する実態調査

    田口　和明、榎木　裕紀、有賀　聡美、榊原　幹夫、堀　里子、山浦　克典、松元　一明

    第31回日本医療薬学会年会, 

    2021.10
    , 

    Poster presentation

  • 赤血球バイオミメティックによる生理活性ガス送達戦略と難治性疾患治療への展開

    田口 和明

    第37回日本DDS学会学術集会, 

    2021.06
    , 

    Oral presentation (invited, special)

  • Medical application of hemoglobin-based artificial blood by delivering carbon monoxide

    Kazuaki Taguchi, Toru Maruyama, Kazuaki Matsumoto, Hiromi Sakai, Masaki Otagiri

    第85回日本循環器学会学術集会, 

    2021.03
    , 

    Symposium, workshop panel (nominated)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • ヘモグロビンを基盤とした次世代型高感度ナノMRI造影剤の開発

    2022.06
    -
    2025.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 挑戦的研究（萌芽）, Principal investigator

  • サイトカインストーム制圧を目指したマクロファージ標的化一酸化炭素ナノ供与体の創製

    2022.04
    -
    2026.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 基盤研究(B), Principal investigator

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019.04
    -
    2021.03

    橋渡し研究戦略的推進プログラム　シーズA, Other, Principal investigator

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014.04
    -
    2017.03

    科学研究費補助金・若手研究B, Research grant, Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied： 特願2020-144044,PCT/JP2021/ 31458  2020.08 

    Patent, Joint

  • 横紋筋融解症治療剤

    Date issued： 特許第6523842号  2019.05

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • 熊本大学学長賞

    2011.03

  • 日本薬学会九州支部学術奨励賞

    2017.12

  • 日本薬学会奨励賞

    2020.03

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本DDS学会奨励賞 (臨床)

    2021.06, 日本DDS学会

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本薬物動態学会奨励賞

    2021.11, 日本薬物動態学会

    Type of Award： International academic award (Japan or overseas)

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2023

  • SEMINAR (PHARMACODYNAMICS)

    2023

  • RESEARCH FOR BACHELOR'S THESIS 1

    2023

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2023

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2023

display all >>

Page Top ▲